NCT02478879

A Study to Determine the Patient Preference Between Zosano Pharma Parathyroid Hormone (ZP-PTH) Patch and Forteo Pen

An Open-label Crossover Study to Determine the Patient Preference Between ZP-PTH Patches and Forteo Pens After Daily Treatment for 14 Days in Women 55-85 Years of Age

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: Zosano Pharma Corporation · Industry
• Sex: Female
• Age: 55 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine which of two delivery methods of Parathyroid Hormone (PTH) is preferred by patients after 14 days of use for each.

Detailed description

The purpose of this study is to determine which of two delivery methods of PTH is preferred by patients after 14 days of use for each. Patient preference will be determined by means of patient questionnaires at the end of each treatment period and a final questionnaire after both treatment periods are complete. Adverse events will also be collected.

Conditions

• Postmenopausal Osteoporosis

Interventions

Type	Name	Description
DRUG	ZP-PTH	Patch applied daily for 30 minutes, 14 days
DRUG	FORTEO	Subcutaneous injection administration daily for 14 days

Timeline

• Start date: 2015-06-01
• Primary completion: 2015-11-01
• Completion: 2015-12-01
• First posted: 2015-06-23
• Last updated: 2016-08-23

Locations

1 site across 1 country: United States